Ebola nurse ‘serious’ as epidemic fades

File photo of nurse Pauline Cafferkey

Risks linger even as vaccines tested in Africa

Bupa to sell 200 UK care homes

Auction comes amid widening losses and government spending cuts

Clinton, the TPP and the trust problem

The Democratic frontrunner’s about-turn does not do her credit

Big pharma thinks twice about price rises

Valeant and Allergan chiefs signal end to ‘buy and raise’ deals

Valeant’s business model faces scrutiny

US pharma group questioned about organic growth potential

Actavis; pills; drugs

Express Scripts agrees heart drugs deal

Pharmacy group wins discount on medicine’s $14,000-a-year price

Axovant in late-stage Alzheimer’s trials

Group aims to win green light for first treatment for the disease since 2003

Cell Therapy eyes initial public offering

Cardiff-based company is developing regenerative medicines

Broccoli powers UK pharma group to float

Evgen Pharma joins procession of drug developers aiming to list

Week in Review

Week in Review, October 3

Shell’s broken Arctic dream; Valeant, digital ads and Liberty Global also in the news

Bayer cuts price range for Covestro IPO

Gross proceeds slashed from €2.5bn to €1.5bn after China worries

Healthcare junk bonds sting investors

Yields jump after drugs groups accused of price gouging

Cyborg brains are heading this way, soon

World must look beyond medical marvels of memory enhancement

Valeant: return to sender

The drugmaker’s shares have been hit, but is it cheap?

Implant can encode human memories

Prosthetic gives hope to Alzheimer’s sufferers and wounded soldiers who cannot remember recent past

US lawmakers target Valeant drug pricing

Shares plunge as politicians probe sharp price hikes

NHS brings outsourcing surge to a halt

Failed or botched contracts knock confidence in private sector

Multicultural Birmingham aids clinical trials

Millions spent recasting the city as a life science hub

Patient lobby groups can be a catalyst for new therapies

Community support bodies are a powerful force behind funding, research and drug approval

Patients need faster, cheaper treatment

Scientific advances are not being translated into therapies quickly enough


More FT Twitter accounts